AR049149A1 - Analogos antagonistas de gh-rh - Google Patents

Analogos antagonistas de gh-rh

Info

Publication number
AR049149A1
AR049149A1 ARP040102755A ARP040102755A AR049149A1 AR 049149 A1 AR049149 A1 AR 049149A1 AR P040102755 A ARP040102755 A AR P040102755A AR P040102755 A ARP040102755 A AR P040102755A AR 049149 A1 AR049149 A1 AR 049149A1
Authority
AR
Argentina
Prior art keywords
cit
arg
har
hes
ala
Prior art date
Application number
ARP040102755A
Other languages
English (en)
Inventor
A Schally
J Varga
M Zarandi
R Cai
Original Assignee
Us Health
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, Univ Tulane filed Critical Us Health
Publication of AR049149A1 publication Critical patent/AR049149A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/60Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se provee una serie de análogos antagonistas sintéticos de hGH-RH(1-29)NH2. Estos análogos inhiben la actividad de hGH-RH endogena en los receptores de GH-RH de la pituitaria y, por lo tanto, previenen la liberacion de la hormona de crecimiento. También los análogos inhiben la proliferacion de cánceres humanos a través de un efecto directo sobre las células cancerosas. Las potencias más altas de los nuevos análogos, en comparacion con los anteriores descritos, resulta del reemplazo de varios amino ácidos. Reivindicacion 1: Un péptido seleccionado del grupo que tiene la formula: R1-A0-A1-A2-Asp-Ala-A5-A6-Thr-A8-A9-A10-A11-A12-Val-Leu-A15-A16-Leu-Ser-A19-A20-A21-A22-Leu-Gln-Asp-IIe-A27-A28-A29-A30-R2, en que R1 es un miembro del grupo que consiste de a) PhAc, Hca, Dat, IndAc, Ipa, 1-Nac, 2-Nac, 1-Npr, 2-Npr, Ibu; CH3(CH2)nCO, o HOOC(CH2)nCO, en que n es un entero desde 2 hasta 20 y b) es cualquier otro grupo carbocíclico o heterocíclico aromático, de cadena recta, o cadena ramificada, saturado, insaturado o poli-insaturado, con desde 3 hasta 8 átomos de carbono, conteniendo al menos un átomo del grupo de S, N y O en el anillo heterocíclico, A0 es Phe, D-Phe, Arg, D-Arg, o un enlace simple carbono-nitrogeno, A1 es Tyr o Hes, A2 es D-Arg o D-Cit, A5 es IIe o Val, A6 es Phe, Tyr, Nal, o Phe(Y), en que Y=F, Cl, Br, o I, A8 es Asn, D-Asn, Cit, D-Cit, Gln, D-Gln, Ser, D-ser, Thr, D-Thr, Ala, D-Ala, Abu, D-Abu, o Aib, A9 es Hes, D-Hes, Amp, D-Amp, Gup o D-Gup, A10 es Tyr, Tyr(Et), Tyr(Me); Phe(Y), en que Y=H; F, Cl, Br, o I; Amp, Hes, Cha, Chg, Bpa, Dip, Trp, Trp(For), Tpi, 1-Nal, 3-Pal , 4-Pal, Phe(NH2), o Phe(NO2), A11 es Hes, D-Hes, Arg, D-Arg, Cit, Har, D-Har, Amp, D-Amp, Gup, o D-Gup, A12 es Lys, D-Lys, Orn, D-Orn, Har, D-Har, Cit, D-Cit, Nle, o Ala; A15 es Gly, Ala, Abu, Aib, Nle, Gln, Cit, o Hes; A16 es Gln o Arg; A19 es Ala o Abu; A20 es Hes, D-Hes, Arg, D-Arg, o Cit; A21 es Lys, D-Lys, Orn, D-Orn, Cit, o D-Cit; A22 es Leu, Ala o Aib; A27 es Met, Leu, Nle, Abu, o D-Arg; A28 es Arg, D-Arg, Har, D-Har, Ser, Asn, Asp, Ala, Abu, o Cit; A29 es Arg, D-Arg, Har, D-Har, Cit, D-Cit, o Agm, A30 es Arg, D-Arg, Har, D-Har, Cit, D-Cit, Agm, o es un enlace simple carbono-nitrogeno o carbono-oxígeno; R2 es -NH2, -NH-NH2, -NH-OH, -NHR3, -NR3R4, -OH, u -O3, en que R3 y R4 son cualquiera de alquil C1-10, alquenil C2-10, alquinil C2-10, fenilalquil C7-16, -C6H5, o -CH(C6H5)2; con la salvedad que si A29 es Agm, entonces A30 y R2 están ausentes y, si A30 es Agm, entonces R2 está ausente, y la sales farmacéuticamente aceptables de los mismos.
ARP040102755A 2003-08-05 2004-08-03 Analogos antagonistas de gh-rh AR049149A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49270603P 2003-08-05 2003-08-05

Publications (1)

Publication Number Publication Date
AR049149A1 true AR049149A1 (es) 2006-07-05

Family

ID=34193144

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102755A AR049149A1 (es) 2003-08-05 2004-08-03 Analogos antagonistas de gh-rh

Country Status (19)

Country Link
US (1) US7452865B2 (es)
EP (1) EP1651662A4 (es)
JP (1) JP2007526900A (es)
KR (1) KR20060088875A (es)
CN (1) CN1871020A (es)
AR (1) AR049149A1 (es)
AU (1) AU2004265280A1 (es)
BR (1) BRPI0413257A (es)
CA (1) CA2534436A1 (es)
IL (1) IL173201A0 (es)
MX (1) MXPA06001369A (es)
NO (1) NO20061060L (es)
PL (1) PL380437A1 (es)
RS (1) RS20060086A (es)
RU (1) RU2335506C2 (es)
SG (1) SG136958A1 (es)
TW (1) TW200517400A (es)
WO (1) WO2005016953A2 (es)
ZA (1) ZA200600966B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009108364A2 (en) * 2008-02-27 2009-09-03 Ipsen Pharma S.A.S. Antagonistic analogues of ghrh
AU2009228244A1 (en) * 2008-03-28 2009-10-01 The United States Of America Represented By The United States Department Of Veteran's Affairs Novel N-and C-terminal substituted -antagonistic analogs of human GH-RH
US8691942B2 (en) 2008-03-28 2014-04-08 University Of Miami N- and C- terminal substituted antagonistic analogs of GH-RH
US8796216B2 (en) 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
CN107446053A (zh) 2008-06-12 2017-12-08 益普生生物创新有限公司 癌症的抑制
KR101642363B1 (ko) * 2008-06-12 2016-07-25 입센 바이오이노베이션 리미티드 신경내분비계 질환의 억제
US8227421B2 (en) * 2009-09-17 2012-07-24 University Of Miami Fluorinated GHRH antagonists
WO2011153491A2 (en) 2010-06-03 2011-12-08 University Of Miami Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets
CN103547591A (zh) 2011-04-21 2014-01-29 瑟瑞技术公司 生长激素释放因子(grf)类似物及其用途
US9079974B2 (en) * 2011-12-21 2015-07-14 The University Of Miami GH-RH analogs with potent agonistic effects
EP2866894A4 (en) * 2012-06-27 2016-03-16 Univ Miami COMPOSITION AND METHOD FOR THE TREATMENT OF MORBUS ALZHEIMER
US9855312B2 (en) 2012-12-21 2018-01-02 University Of Miami GHRH agonists for the treatment of ischemic disorders
EP2935317B1 (en) 2012-12-21 2019-03-27 University of Miami Ghrh agonists for islet cell transplantation and function and the treatment of diabetes
AU2020218272A1 (en) 2019-02-08 2021-09-02 United States Government As Represented By The Department Of Veterans Affairs Growth hormone-releasing hormone antagonists and uses thereof
CA3178840A1 (en) 2020-04-27 2021-11-04 The University Of Miami Method of treating an inflammatory disorder
CN114195881B (zh) * 2021-12-16 2022-09-16 浙江湃肽生物股份有限公司 一种制备醋酸舍莫瑞林的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942489A (en) * 1996-05-03 1999-08-24 The Administrators Of The Tulane Educational Fund HGH-RH(1-29)NH2 analogues having antagonistic activity
US6057422A (en) * 1998-11-25 2000-05-02 The Administrators Of The Tulane Educational Fund Antagonistic analogs of GH-RH inhibiting IGF-I and -II

Also Published As

Publication number Publication date
RU2335506C2 (ru) 2008-10-10
SG136958A1 (en) 2007-11-29
WO2005016953A3 (en) 2006-02-09
EP1651662A4 (en) 2009-07-01
TW200517400A (en) 2005-06-01
US20070042950A1 (en) 2007-02-22
CA2534436A1 (en) 2005-02-24
WO2005016953A2 (en) 2005-02-24
EP1651662A2 (en) 2006-05-03
JP2007526900A (ja) 2007-09-20
KR20060088875A (ko) 2006-08-07
CN1871020A (zh) 2006-11-29
ZA200600966B (en) 2007-05-30
RU2006106701A (ru) 2007-09-20
MXPA06001369A (es) 2007-02-19
PL380437A1 (pl) 2007-01-22
AU2004265280A1 (en) 2005-02-24
NO20061060L (no) 2006-05-03
BRPI0413257A (pt) 2006-10-03
RS20060086A (en) 2008-08-07
US7452865B2 (en) 2008-11-18
IL173201A0 (en) 2006-06-11

Similar Documents

Publication Publication Date Title
AR049149A1 (es) Analogos antagonistas de gh-rh
KR100582510B1 (ko) 엘에이치-알에이치 단백질 효능제 또는 길항제, 이의 용도 및 이를 함유하는 약제학적 조성물
Morley Structure-function relationships in gastrin-like peptides
AU2002322466B2 (en) Linear and cyclic melanocortin receptor-specific peptides
JPH05503689A (ja) GnRH類似体
US7335723B2 (en) Melanin-concentrating hormone antagonists
UY25327A1 (es) Péptidos opioides sintéticos que ejercen su acción agonista actuando selectivamente sobre receptores opioides kappa
RU2000100369A (ru) Аналоги пептида лг-рф, их применение и содержащие их фармацевтические композиции
RU2015143472A (ru) Конъюгаты инсулин-инкретин
AU2002322466A1 (en) Linear and cyclic melanocortin receptor-specific peptides
KR960701653A (ko) 펩타이드 yy의 유사체 및 그의 용도
KR940005670A (ko) 펩티드
AR003475A1 (es) Nuevos peptidos opiaceos, composiciones farmaceuticas que los contienen, el uso de los mismos en la preparacion de formulaciones y un metodo para su preparacion.
GB1498048A (en) Decapeptide amides
AR019131A1 (es) Analogos de polipeptidos pituitarios que activan la adenilato ciclasa, una composicion farmaceutica que los comprende, y el uso de dichos peptidos para lamanufactura de un medicamento
AR066175A1 (es) Ligandos del receptor de melanocortina de peptidos ciclicos
KR930702386A (ko) 노나펩티드 봄베신 길항제
CA2199325A1 (en) Cyclic analogs of pth and pthrp
JPS61194098A (ja) 脂肪族‐芳香族ケトン側鎖を含むペプチド
KR840002772A (ko) 뇌하수체 성장호르몬 유리작용을 지닌 펩타이드의 합성방법
KR930701483A (ko) Grf (쥐이알에프) 유사체 xi
RU2013146690A (ru) Циклические пептиды с антинеопластической и антиангионенной активностью
EP0592512A1 (en) NON-DESENSITIZING ANALOGS OF GnRH AND OTHER BIOLOGICALLY ACTIVE LIGANDS
US5872100A (en) Peptides containing D-2-Alkyl-Tryptophan
KR100240434B1 (ko) 구조적으로 변형된 혈관작용성 소장 펩티드(vip)의 유도체 및 이를 함유한 제약 조성물

Legal Events

Date Code Title Description
FB Suspension of granting procedure